使用现代影像方法促进前列腺癌寡转移疾病转移导向治疗的试验:EORTC影像组的共识建议
本文为EORTC影像组共识建议,评估用于识别前列腺癌初诊、生化复发或去势抵抗阶段转移的影像方法。指南推荐的标准影像方法诊断准确性不足以可靠诊断寡转移疾病;使用肿瘤特异性放射性示踪剂(胆碱或前列腺特异性膜抗原配体)的PET-CT及日益广泛应用的全身MRI扩散加权成像可更早、更精确识别转移。EORTC影像组提出临床算法将现代影像方法整合到各阶段诊疗路径中以识别寡转移疾病,并提议使用现代影像方法评估转移导向治疗获益的临床试验。
要点
- 指南推荐的标准影像方法诊断准确性不足以可靠诊断寡转移疾病。
- 使用胆碱或PSMA配体PET-CT及全身MRI扩散加权成像可更早、更精确识别转移。
- EORTC影像组提出临床算法将现代影像方法整合到前列腺癌各阶段以识别寡转移疾病。
核心结论
- EORTC影像组建议将现代影像方法(PET-CT联合肿瘤特异性放射性示踪剂、全身MRI扩散加权成像)整合到前列腺癌各阶段诊疗路径中以识别寡转移疾病,并提议开展使用现代影像方法评估转移导向治疗获益的临床试验。
研究设计与样本
- 本文为欧洲癌症研究与治疗组织(EORTC)影像组发布的共识建议(综述类),评估用于识别前列腺癌初诊、生化复发或去势抵抗阶段转移的影像方法,未报告系统检索范围与纳入文献数量。
诊断标准与关键数值
- 指南推荐的标准影像方法诊断准确性不足以可靠诊断寡转移疾病;使用肿瘤特异性放射性示踪剂(胆碱或前列腺特异性膜抗原配体)的PET-CT及全身MRI扩散加权成像可更早、更精确识别转移。
临床应用与阅片要点
- EORTC影像组提出临床算法,将现代影像方法整合到前列腺癌初诊、生化复发或去势抵抗各阶段的诊疗路径中以识别寡转移疾病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Oligometastatic disease represents a clinical and anatomical manifestation between localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition of oligometastatic disease enables focal, metastasis-directed therapies. These therapies potentially shorten or postpone the use of systemic treatment and can delay further metastatic progression, thus increasing overall survival. Metastasis-directed therapies require imaging methods that definitively recognise oligometastatic disease to validate their efficacy and reliably monitor response, particularly so that morbidity associated with inappropriately treating disease subsequently recognised as polymetastatic can be avoided. In this Review, we assess imaging methods used to identify metastatic prostate cancer at first diagnosis, at biochemical recurrence, or at the castration-resistant stage. Standard imaging methods recommended by guidelines have insufficient diagnostic accuracy for reliably diagnosing oligometastatic disease. Modern imaging methods that use PET-CT with tumour-specific radiotracers (choline or prostate-specific membrane antigen ligand), and increasingly whole-body MRI with diffusion-weighted imaging, allow earlier and more precise identification of metastases. The European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group suggests clinical algorithms to integrate modern imaging methods into the care pathway at the various stages of prostate cancer to identify oligometastatic disease. The EORTC proposes clinical trials that use modern imaging methods to evaluate the benefits of metastasis-directed therapies.
引用
- Lecouvet FE, Oprea-Lager DE, Liu Y, et al. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncol. 2018. PMID: 30303127. doi:10.1016/S1470-2045(18)30571-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。